Celecoxib versus diclofenac in the management of osteoarthritis of the knee: A placebo-controlled, randomised, double-blind comparison
Autor: | F. McKenna, J. B. Lefkowith, G. S. Geis, H. Wendt, C. Wallemark, David G. Borenstein |
---|---|
Rok vydání: | 2001 |
Předmět: |
musculoskeletal diseases
business.industry Immunology General Medicine Osteoarthritis medicine.disease Placebo law.invention stomatognathic diseases Diclofenac Rheumatology Tolerability Randomized controlled trial law Joint pain Anesthesia Celecoxib Immunology and Allergy Medicine heterocyclic compounds Onset of action medicine.symptom business medicine.drug |
Zdroj: | Scandinavian Journal of Rheumatology. 30:11-18 |
ISSN: | 1502-7732 0300-9742 |
Popis: | Objective: A clinical trial was conducted in 600 patients with OA of the knee to test the hypothesis that the specific COX-2 inhibitor, celecoxib, has equivalent efficacy and a superior tolerability/safety profile when compared to diclofenac, the current worldwide standard of care. Methods: Patients were administered celecoxib 100 mg BID, diclofenac 50 mg TID or placebo for 6 weeks in a multicentre, double-blind, placebo-controlled trial. Results: Primary efficacy measures (index joint pain by VAS, WOMAC index) indicated statistically significant improvement versus placebo for both celecoxib and diclofenac and no statistically significant differences between celecoxib and diclofenac. American Pain Society (APS) measures to assess the rapidity of onset of action showed statistically significant and comparable pain relief versus placebo within 24 h for both celecoxib and diclofenac. More diclofenac patients reported GI side effects than patients treated with either placebo or celecoxib. Diclofenac-treated p... |
Databáze: | OpenAIRE |
Externí odkaz: |